TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Zacks
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Teva Pharmaceutical Industries Q2 26 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Teva Pharmaceutical Industries (TEVA) will host a conference call at 8:00 AM ET on July 29, 2026, to discuss Q2 26 earnings results...
Nasdaq News: Markets
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Teva Pharmaceutical Industries (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Zacks
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.